Rebecca Taub, President, R&D, and CMO at MADRIGAL PHARMACEUTICALS, INC. (MDGL), sold 4,028 shares at $247.76 ($990K) on 2024-04-08, disclosed to the SEC on 2024-04-10.
Scheduled sale ($990k) by President, R&D, and CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $243.25 | 224 | $54K | 5.5% |
| 2 | $244.79 | 945 | $231K | 23.4% |
| 3 | $244.79 | 945 | $231K | 23.4% |
| 4 | $245.69 | 300 | $74K | 7.4% |
| 5 | $246.98 | 600 | $148K | 15.0% |
| 6 | $247.76 | 407 |
| $101K |
| 10.2% |
| 7 | $247.76 | 407 | $101K | 10.2% |
| 8 | $248.58 | 200 | $50K | 5.0% |
| Total | $245.89 avg | 4,028 | $990K | 100% |
| Filing → |
| MDGL | SELL | 2026-01-20 | $1.1M | — | Filing → |
| MDGL | SELL | 2026-01-13 | $18.9M | — | Filing → |
| MDGL | SELL | 2026-01-13 | $242K | — | Filing → |